Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis by Mole, SE et al.
Mole, SE and Anderson, G and Band, HA and Berkovic, SF and Cooper, JD
and Kleine Holthaus, SM and McKay, TR and Medina, DL and Rahim, AA and
Schulz, A and Smith, AJ (2019) Clinical challenges and future therapeutic
approaches for neuronal ceroid lipofuscinosis. The Lancet Neurology, 18 (1).





Usage rights: Creative Commons: Attribution-Noncommercial-No Deriva-
tive Works 4.0
Please cite the published version
https://e-space.mmu.ac.uk
www.thelancet.com/neurology   Vol 18   January 2019 
Lancet Neurol 2018; 18: 107–16
Published Online 
November 20, 2018 
http://dx.doi.org/10.1016/
S1474-4422(18)30368-5
Medical Research Council 
Laboratory for Molecular Cell 
Biology and UCL Great Ormond 
Street Institute of Child Health 
(Prof S E Mole PhD), UCL 
Institute of Ophthalmology 
(S-M kleine Holthaus PhD, 
A J Smith PhD), and UCL School 
of Pharmacy (A A Rahim PhD), 
University College London, 
London, UK; Department of 
Histopathology, Great Ormond 
Street Hospital, London, UK 
(G Anderson FIBMS); Batten 
Disease Family Association, 
Farnborough, UK 
(H A Band MSc); Epilepsy 
Research Centre, Department 
of Medicine, Austin Health & 
Northern Health, University of 
Melbourne, Melbourne, VIC, 
Australia (Prof S F Berkovic MD); 
Department of Pediatrics, 
Washington University School 
of Medicine, St Louis, MO, USA 




(Prof T R McKay PhD); Telethon 
Institute of Genetics and 
Medicine, Naples, Italy 
(D L Medina PhD); and 
Department of Pediatrics, 





Prof Sara E Mole, Medical 
Research Council Laboratory for 
Molecular Cell Biology, University 
College London, London, 
WC1E 6BT, UK 
s.mole@ucl.ac.uk
Clinical challenges and future therapeutic approaches for 
neuronal ceroid lipofuscinosis
Sara E Mole, Glenn Anderson, Heather A Band, Samuel F Berkovic, Jonathan D Cooper, Sophia-Martha kleine Holthaus, Tristan R McKay, 
Diego L Medina, Ahad A Rahim, Angela Schulz, Alexander J Smith
Treatment of the neuronal ceroid lipofuscinoses, also known as Batten disease, is at the start of a new era because of 
diagnostic and therapeutic advances relevant to this group of inherited neurodegenerative and life-limiting disorders 
that affect children. Diagnosis has improved with the use of comprehensive DNA-based tests that simultaneously screen 
for many genes. The identification of disease-causing mutations in 13 genes provides a basis for understanding the 
molecular mechanisms underlying neuronal ceroid lipofuscinoses, and for the development of targeted therapies. 
These targeted therapies include enzyme replacement therapies, gene therapies targeting the brain and the eye, cell 
therapies, and pharmacological drugs that could modulate defective molecular pathways. Such therapeutic developments 
have the potential to enable earlier diagnosis and better targeted therapeutic management. The first approved treatment 
is an intracerebroventricularly administered enzyme for neuronal ceroid lipofuscinosis type 2 disease that delays 
symptom progression. Efforts are underway to make similar progress for other forms of the disorder. 
Introduction
The neuronal ceroid lipofuscinoses (NCLs), also known 
as Batten disease, are a group of monogenic inherited 
neurodegenerative disorders that mostly present in the 
first decade of life.1 They share a broadly similar clinical 
presentation characterised by seizures, visual failure, and 
a progressive decline in cognitive and motor abilities due 
to progressive neuronal death. However, these disorders 
also show variation, most notably in the age of onset, rate 
of disease progression, and first symptoms.1 Regardless, 
all forms of NCLs are fatal and no curative treatments are 
available.
Pathologically, these disorders are profoundly neuro­
degenerative, and share a common hallmark of accumula­
tion of autofluorescent material in lysosomes, called ceroid 
and lipofuscin, that has a typical ultrastructural appearance 
under electron microscopy but does not appear to relate 
directly to neuron loss.2 Although the precise underlying 
mechanisms remain elusive, disease­causing mutations 
have been revealed in 13 different genes: PPT1, TPP1, 
DNAJC5, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD, 
GRN, ATP13A2, CTSF, and KCDT7.3,4 The increasing 
imple mentation of next genera tion sequencing panels and 
exome sequencing as essential diagnostic tools leads to 
more diagnoses of patients with NCL, including those 
varying from the typically recognised phenotypes due 
to so­called milder mutations. This has necessitated a 
change in disease nomenclature based on the gene defect 
augmented with age of presentation.4
There has been an emphasis on understanding the 
staging of these disorders and their molecular pathways, 
and advancing experimental therapies such as enzyme 
replacement and gene therapy in animal models,5–8 
together with the establishment of patient registries9,10 and 
disease rating scales.11,12 These efforts have culminated in 
the approval by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) of the 
first treatment for a NCL disorder: enzyme replacement 
therapy for neuronal ceroid lipofuscinosis type 2 (CLN2) 
disease.13,14 Much preclinical work followed by clinical 
trials is required before treatment is available for all forms 
of NCLs. This Review provides an update on clinical 
features, genotype–phenotype correlations, pathology, and 
discusses the most promising therapeutic approaches 
of NCLs.
Clinical characteristics
All patients with NCLs, except for those with a rare 
congenital form (neuronal ceroid lipofuscinosis type 10 
[CLN10] disease), have a normal psycho motor development 
before onset of first symptoms.1 Age at disease onset is in 
childhood for most patients, but for some can be as late as 
60 years or older (table 1). The main symptoms are a 
combination of at least two of the following: dementia, 
epilepsy, motor deterioration, and visual loss.1 The order in 
which symptoms occur varies and depends on the com­
bination of the underlying mutations, which can affect age 
at onset and disease phenotype.1 The number of pheno­
types for NCL diseases is growing and the widest age range 
of onset is for those NCLs arising from  lyso somal enzyme 
deficiencies (table 1).3 Increasing knowledge about the 
natural history of the different forms of NCLs has shown 
that for some genes the phenotype severity can vary 
substantially even between siblings, as in juvenile neuronal 
ceroid lipofuscinosis type 3 (CLN3) disease.16 Symptoms 
can also be outside the CNS. For example, cardiac 
involvement has been reported in adolescent and adult 
patients with CLN3 disease17,18 and can be treated (eg, 
fitting of a pacemaker has improved a patient’s psycho­
motor abilities).16
First symptoms in classic infantile (age of onset 
6–24 months) and late­infantile (age of onset 2–5 years) 
phenotypes are slowing of psychomotor development, 
quickly followed by standstill, then progressive loss of 
acquired psychomotor abilities and onset of epilepsy, 
and lastly followed by vision loss.1 This regression is 
often mistaken for a side­effect of antiepileptic drugs, 
delaying diagnosis. By contrast, first symptoms in the 
juvenile phenotype (age of onset 5–7 years) are usually 
visual loss, followed by dementia and behaviour changes, 
and then loss of motor skills and epilepsy in the early 
adolescence.1 In recessive adult phenotypes (more than 
16 years of age) also referred to as Kufs disease, visual 
loss is usually absent, and patients present with pro­
gressive myoclonus epilepsy (type A) or dementia with 
motor decline (type B) typically around age 30 years, but 
symptom onset could range from 16 to 50 years of age.19
Even though all types of NCLs share a similar set 
of clinical features (eg, dementia, epilepsy, motor de­
terioration, and visual loss) their clinical severity and 
pre sentation often differs even for those caused by 
muta tions in the same gene. Delay in expressive language 
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Note CLN9 is not identified. CLN=neuronal ceroid lipofuscinosis type; PPT1=palmitoyl protein thioesterase 1; TPP1= tripeptidyl peptidase 1; DNAJC5=DnaJ homolog subfamily C member 5 (also known as cysteine 
string protein alpha or CSPa); MFSD8=major facilitator superfamily domain-containing protein 8; NCLs=neuronal ceroid lipofuscinoses; CTSD=cathepsin D; NCLs=neuronal ceroid lipofuscinoses; GRN=granulin; 
CTSF=cathepsin F; SCAR7= autosomal recessive spinocerebellar ataxia 7; EPMR=Epilepsy, Progressive, With Mental Retardation. *Variations in further genes have occasionally been linked with NCL-like 
phenotypes: CLN12/ATP13A2, mutations usually cause Kufor-Rakeb syndrome; CLN14/KCTD7 in cases with infantile and late infantile onset, all other known mutations cause a progressive myoclonic epilepsy or 
opsoclonus-myoclonus ataxia-like syndrome; SGSH in a case with adult onset, all other known mutations cause mucopolysaccharidosis type IIIA; CLCN6, perhaps modifying disease phenotype.3 † Non-NCL 
disease phenotype that could be more typically associated with other genes. ‡Phenotype caused by complete loss of gene function. §Only the mutations that cause NCL  when present on both disease alleles is 
enumerated; these mutation, and other mutations in this gene, cause later onset frontotemporal lobar dementia when present in heterozygous form.15
Table 1: Correlation between genotype and phenotype in neuronal ceroid lipofuscinoses
development is the first sign of regression of psychomotor 
function in 83% of patients with classic late­infantile CLN2 
disease and could enable early diagnosis.9 Children with a 
combination of language acquisition delay and new onset 
of seizures should be tested for CLN2 disease.9,20 Epilepsy 
is therapy­resistant in almost all patients with NCLs, with 
especially high seizure frequency and severity in late­
infantile CLN2 disease up until late stages of disease.20 
However, in infantile neuronal ceroid lipofuscinosis type 1 
(CLN1) disease, seizure frequency tends to decrease in the 
later stages of disease; in patients with classic juvenile 
CLN3 disease, seizures are in frequent with only mild 
worsening with later stages of disease.21,22 Therapy with 
more than two antiepileptic drugs could result in increased 
side­effects rather than a reduction of seizures.1 Some anti­
epileptic drugs are particularly recommended—valproate 
and lamotrigine for CLN2 and CLN3 diseases;21,22 how­
ever, others (eg, carbamazepine, gabapentin, phenytoin, or 
vigabatrin) might have negative effects—they c ould 
exacerbate myoclonic seizures in patients with CLN2 or 
CLN3 disease.21–23 As disease progresses, anticonvulsive 
drugs that have been tolerated and effective might cause 
new side­effects, and should be reconsidered if symptoms 
of the dis ease worsen.22
Motor signs range from ataxia (including dysmetria 
and dysarthria) and dysphagia to myoclonus, chorea, 
tremor, and dystonia, especially in classic infantile and 
late­infantile phenotypes.1 Others include parkinsonism, 
especially in juvenile CLN3 disease, and some stereo­
typical movements have been reported in various types of 
NCLs with late­infantile and juvenile age of onset.1
More NCL disease phenotypes are being recognised in 
which one of the clinical hallmarks might be more pre­
dominant and others absent. For example, in a rare type of 
CLN2 disease (autosomal recessive spinocerebellar ataxia 
type 7), ataxia is the primary phenotype with no accom­
panying epilepsy or vision loss,24 and in one type of juvenile 
CLN2 disease associated with a particular mutation, 
survival is into the fourth decade of life.25 Some patients 
with mutations in CLN3 have only isolated non­syndromic 
recessive retinal degeneration,26 and others experience 
visual failure, seizures, and cardiac involvement, but no 
motor deterioration even many decades after disease 
onset.27 A pathophysiological link between NCLs and 
an adult degenerative dementia is assumed given that 
homo zygous mutations in GRN cause NCLs presenting at 
around age 20 years with visual failure, seizures, and 
ataxia, whereas heterozygous mutations in this gene are a 
common cause of frontotemporal lobar degeneration with 
TDP­43 inclusions.3,15
Neuroimaging and EEG findings
Brain MRI scans can look normal in the early stages of the 
disease or might show some unspecific s igns, s uch a s 
periventricular intensity changes in early­stage CLN2 
disease.28 Although MRI is not sensitive or specific f or 
early diagnosis, it is an excellent tool to objectively monitor 
the progression of brain changes, particularly with ad­
vances in resolution and processing, and neuro imaging 
techniques such as diffusion tensor imaging allow assess­
ment of disorganisation of white matter tracts and atrophy. 
Two prospective studies28,29 in patients with CLN2 disease 
have shown that the loss of cortical grey matter volume 
with increasing age might be a sensitive biomarker to 
monitor disease progression.
EEG can be helpful in early diagnosis of some NCLs. 
For example, characteristic posterior spike waves were 
reported after low­frequency photic stimulation in 
13 (93%) of 14 patients with early stage of CLN2 disease.30 
Finding posterior spike waves after photic stimulation in a 
child younger than 5 years with a new onset of seizures 
should trigger testing for CLN2 disease.30,31 Photosensitivity 
with low­frequency stimulation has also been reported in 
patients with neuronal ceroid lipofuscinosis type 6 (CLN6) 
disease, and especially in those with adult CLN6 disease 
(type A).32–34 In NCL forms that rapidly progress, such as 
infantile CLN1 disease, early abnor malities disappear as 
neurons die, leading to a char acteristic flat EEG at 
advanced stages of disease.1 Because of the underlying 
neurometabolic disease, antiepileptic drugs will not lead 
to normalisation of the EEG findings,1 presumably 
because cells have died or are dying, and this in itself leads 
to seizures. Monitoring by EEG might be useful for 
detecting signs of encephalitis, which could be a rare 
consequence of antiepileptic drugs such as valproate in 
advanced late­infantile CLN2 disease,22 or theoretical 
allergic reaction to new treatments.
Genotype–phenotype correlations
The NCLs are monogenic disorders, so each is a separate 
disease entity. The genes associated with NCLs encode 
apparently unrelated proteins that include soluble lyso­
somal enzymes and membrane proteins localised in vari­
ous organelles, including the lysosome (table 1).3,35,36 All 
types of NCLs are autosomal recessive with the except­
ion of one rare adult onset NCL, neuronal ceroid lipo­
fuscinosis type 4 (CLN4) disease.3 For most NCLs there is 
a rec ognisable classic disease phenotype associated with 
complete loss of gene function due to intracellular mis­
localisation or degradation of the mutant protein.3 Later 
onset forms of disease that might have a more protracted 
overall course also occur and some antici pated classic 
phenotypes might be absent as a result of milder muta­
tions that do not completely stop protein function (table 
1).19 There are examples of muta tions associated with a 
specific phenotype such as a missense mutation in CLN8 
or the 1 kb intragenic deletion that underlies the most 
common form of NCLs, juvenile CLN3 disease.3 The most 
prevalent mutations are the 1 kb deletion in CLN3 and two 
mutations in CLN2.3 The combination of data collected in 
DEM­CHILD,9,10 NCL Mutation Database, and application 
of NCL disease rating scales11,12 allows correlations to be 
made between the disease and under lying mutations to 
provide some guid ance to the expected disease course, 
For more on DEM-CHILD see 
www.dem-child.eu
For more on the NCL Mutation 
Database see www.ucl.ac.uk/ncl
and to give an approxi mation of frequency and occurrence 
in specific ethnic groups. As the pheno typic spectrum 
broadens, increasing overlap with other rare (eg, inborn 
errors of metabolism) and common diseases (eg, retinal 
dystrophies) that share similar disease mechanisms is 
expected,37 which could lead to better understanding of all 
these diseases.
Diagnosis
Diagnostic strategies vary according to the age of the 
patient, and can be guided by diagnostic algorithms.1 
Enzyme testing can rapidly confirm some NCLs (table 1). 
The advent of new DNA technologies allows testing for 
many genes in a single step regardless of how typical the 
presentation is (eg, a panel can contain NCLs genes among 
a larger group of syndromic and non­syndromic inherited 
epilepsies). Blood film examination allows identification 
of vacuolated lymphocytes, which is a common feature 
of CLN3 disease.38 Ultrastructural examination of a skin 
biopsy or blood sample remains helpful for confirmation 
of NCL disease for atypical forms that are not enzyme 
deficiencies, or have not yet received a genetic diagnosis 
(table 1). Extracerebral storage is readily detected in 
childhood NCLs but not necessarily in NCLs presenting 
in adulthood.19 Prenatal diagnosis is available and can 
be offered to families with a history of NCL disease. 
Preimplantation genetic diagnosis39 or a combination of 
enzyme assay and mutational analysis, perhaps with 
ultrastructural ex amination of chorionic villus samples 
obtained at 12–15 weeks’ gestation, can provide a rapid 
diagnosis.
Pathology
Neuronal loss is profound and widespread in most patients 
with NCLs resulting in cortical grey matter atrophy, 
cerebellar atrophy, and secondary ventricular enlargement. 
The degree of atrophy and ventricular enlargement varies 
between the NCL forms, but is typically preceded by 
clinical symptoms (eg, epilepsy).2,40 Nevertheless, this loss 
of neurons in the cerebral and cerebellar cortices is 
selective because cell loss is not spread evenly throughout 
the brain in childhood NCLs, and the thalamus can be 
severely affected.2,40 In adult onset NCLs, brain atrophy is 
less obvious.2,40 Pronounced microglial and astrocytic 
activation precedes and per haps causes neuron loss,19,41,42 
accurately predicting its dis tribution.41 Brain atrophy of the 
cerebral cortex and enlargement of the subarachnoid 
space and ventricles progresses throughout the disease.2,40 
Atrophy of the cerebellum is variable but evident in the 
later stages of all NCLs.28,29,43 Neuronal depletion in the 
retina commences in the photoreceptor outer segments, 
proceeding to the inner segments, nerve cell bodies, and 
ganglionic layer, and occurs early in CLN3 disease,44,45 while 
other symptoms (eg, epilepsy) precede visual loss in other 
types of NCLs.1,40 In all forms of NCLs lipopigment storage 
material accumulates in macro phages, neurons, and some 
somatic tissues, including vascular endothelial and smooth 
muscle cells.40 Lipo pigments also accumulate in the CNS 
with increasing age, in healthy people, or neurologi­
cal conditions such as mucopolysaccharidoses or GM1 
ganglio sidosis,40 and careful neuropathological assess­
ment is needed to avoid misdiagnosis (eg, early­onset 
Alzheimer’s disease).19
Mice that are genetically modified or have spontaneous 
mutations exist for all NCL genes,5,46 and their char­
acterisation has provided insights into the staging of 
neuropathological changes.6,7 This has revealed differences 
in the extent, timing, and nature of changes41,42 despite 
leading to a similar pathological endpoint. The spinal 
cord has been identi fied as exhibiting important patho­
logy, including loss of neurons, activation of microglia, 
and build­up of lipo pigment storage in Cln1 mice,47 
with impairments of the peri pheral nervous system evi­
dent resembling paroxysmal sympathetic hyperactivity 
in juvenile CLN3 disease.48 Pathological changes have 
also been described in somatic tissues, including heart 
(eg, repolarisation disturbances, ventricular hypertrophy, 
sinus node dysfunction),17 and establishing its re lationship 
to events in the CNS will be important. Know ing where 
and when pathology occurs is crucial for the effective 
targeting of experimental therapies. In this respect, studies 
with animals that have larger brains (eg, sheep and dogs) 
will be required.5,8 In addition to their larger and more 
complex brains for scaling up the delivery of therapies, the 
extent of pathology and its regionalised nature is more 
pronounced in the brains of sheep and dogs with NCLs 
than in corresponding mouse models (possibly because of 
the size difference), and pathology appears to more closely 
re semble that of human cases.6,7 With the ability to 
engineer genetically modified pigs and sheep, such species 
might prove invaluable for further understanding the 
effects of the disease and to improve therapies.
Technical advances
The development of induced pluripotent stem cell (iPSC) 
technology has been crucial for understanding and 
treating genetic diseases using cell models. Cells obtained 
from a skin or blood sample can be genetically re­
programmed to a state of pluripotency and are capable of 
differentiat ing into virtually any cell type, including 
neuronal sub types.49 Neural cells differentiated from 
patient­derived iPSC display autophagic, lysosomal 
maturation, and mito chondrial quality control defects for 
CLN3 disease and tripeptidyl peptidase 1 (TPP1) enzyme 
deficiency for CLN2 disease.50 In 2017, two repositories 
of NCLs iPSC lines became available to academic 
researchers. The Human Pluripotent Stem Cell Initiative 
in the UK, released 12 lines from patients with CLN1, 
CLN3, CLN6, CLN7, CLN8, and CLN10 mutations, and 
in the USA the Beyond Batten Disease Foundation, 
in alliance with the New York Stem Cell Foundation, 
publicised a re source of iPSC generated from 
24 individuals from CLN3 disease families. However, such 
patient­derived cells are genetic ally diverse. The use of 
For more on the Human 
Pluripotent Stem Cell Initiative 
see http://www.hipsci.org
For more on the Beyond Batten 
Disease Foundation see 
https://beyondbatten.org/
Fore more on the New York 
Stem Cell Foundation see 
https://nyscf.org
clustered regularly spaced short palindromic repeats 
(CRISPR)­Cas9 gene editing tech nology to introduce 
specific g enetic c hanges i nto a  p arental p luripotent l ine 
allows the production of isogenic lines representing 
selected mutations of NCL genes that can more readily be 
compared.51 Such repositories, along with further in­
dividually generated iPSC lines52 and engineered stem 
cells, represent the next generation of cellular tools to 
better understand the causes of NCLs. Patient iPSC­
derived neural cells have already been used as a therapeutic 
evalua tion platform for NCLs, including high­throughput 
screening (appendix).
Emerging therapies
There have been extensive studies using ani mal models in 
developing new treatments for NCLs (appendix). The main 
translational approaches are sum marised, begin ning with 
the most advanced and promising approaches.
Enzyme replacement therapy
Intracerebroventricularly administered enzyme replace­
ment therapy in CLN2 disease is the first t reatment 
approved by the FDA and EMA, and treatment is expected 
to be needed throughout the patient’s life.10,53 The deficient 
enzyme TPP1 is ad ministered over 4 h as a recombinant 
proenzyme via a Rickham or Ommaya reservoir into the 
lateral cerebral ventricles at a dose of 300 mg of pro­
tein every 2 weeks into the brain of children with 
CLN2 disease.10 Safety and efficacy were tested in an open­
label, dose­escalation study lasting up to 12 weeks10 that 
enrolled 24 patients aged 3–16 years with CLN2 disease, 
followed by a 48 week period in which they received a 
stable dose of the protein and then had the option to enroll 
into a 240 week extension study. Most patients (21 [92%]) 
had lost some language or motor skills according to the 
CLN2 Clinical Rating Scale by the trial’s start. Of the 
23 (96%) patients who completed the study,10 18 (78%) had 
either a slower than expected disease progression or 
stabilisation of the disease measured by rating the motor 
and language function of patients after at least 96 weeks of 
treatment (median 116 weeks, range 96–145) at the 300 mg 
dose.10 Notably, two of those patients who had the highest 
initial baseline scores maintained these for the duration of 
the study, indicating that starting treatment early is likely 
to be most beneficial. A ntibodies d eveloped a gainst 
the drug but were not linked to safety concerns or a 
poor treatment outcome.54 The 23 patients continue to 
be treated and followed up to evaluate the long­term 
efficacy an d sa fety (N CT02485899). A se cond st udy 
(NCT02678689) has begun to monitor the effects o f 
beginning treatment earlier in the disease course in a 
separate group of patients (table 2). The cross­corrective 
approach of enzyme replacement therapy depends on 
delivered enzyme being recognised by receptors on the 
surface of cells, taken into the cell and trafficked to  th e 
lysosome, and the same enzyme replacement approach 
might be suitable for other types of NCLs caused by 
mutations in lysosomal enzymes (CLN1/palmitoyl protein 
thioesterase [PPT1], CLN2/TPP1, neuronal ceroid lipo­
fuscinosis type 5 [CLN5], CLN10/CTSD, and neuronal 
ceroid lipofuscinosis type 13 [CLN13]/cathepsin F [CTSF]); 
(table 1). The therapy could be deliv ered frequently and 
periodi cally as a recombinant pro duct, or alternatively 
could be produced and released continually within the 
body following gene therapy or cell­based therapy.
Gene therapy
Gene therapy studies using viral vectors to introduce a 
healthy NCL gene into animal models for NCLs have 
mainly focused on targeting the brain for diseases caused 
by lysosomal enzyme deficiencies, which should be less 
challenging to treat than those caused by mutations 
in integral transmembrane­bound proteins because of 
advantages provided by cross­correction.59 Clinical studies 
and animal models suggest that gene therapy approaches 
targeting only the brain10,60 are unlikely to provide thera­
peutic benefit for the NCL­related retinal de generation. A 
combinatorial gene therapy approach that separately treats 
the brain and the eye is likely to be required for optimal 
therapy.61
The first gene therapy phase 1 clinical trial62 was done in 
ten patients with CLN2 disease aged 3–10 years to test the 
safety of introducing a gene therapy vector designed to 
express TPP1 into the brain. The vector was safe but 
there was no slowing of disease progression. Given the 
experience with enzyme replacement therapy,10 a vector 
and delivery that results in TPP1 reaching more cells is 
likely to be required to achieve better therapeutic out­
come. Orphan drug designation has been grant ed for 
adeno­associated virus­mediated gene therapy for CLN1 
and CLN3 diseases, and clinical trials are anticipated. A 
phase 1/2 trial (NCT02725580) in patients with CLN6 
disease to assess intrathecal administration of AAV9­
mediated gene therapy is ongoing (table 2). The preceding 
animal studies in which efficacy of these vectors was 
tested are not yet published, making evaluation of the 
likelihood of clinical benefit difficult.63,64
Pharmacological approaches
As for most lysosomal storage disorders, many of the 
pharma cological treatments for NCLs are palliative, fo­
cused on minimising clinical symptoms such as seizures, 
and do not target the underlying cause of the disease.1 
Animal models and clinical observations have provided a 
variety of potential targets to modulate disease (eg, anti­
inflammatories, molecular chaperones, enzyme mimics, 
Bcl­2 upregulators, NMDA and AMPA receptor anta gonists, 
calcium­channel blockers, immuno suppres sants, and 
antioxidants).55,65–69 However, follow­up studies using these 
compounds have not shown clinically mean ing ful benefits 
for patients,57,58 including targeting neuro inflammation in 
the eye for CLN3 disease.70 Some parents giving the drug 
flupirtine to their children with juve nile CLN3 disease 
have anecdotally reported benefit; how ever, quantitative, 
See Online for appendix
prospectively obtained data did not show any change in 
disease progression that could be attributed to this drug.71 
A clinical trial treat ing 19 children with juvenile CLN3 
disease with a non­steroidal immunosuppressive drug, 
mycophenolate mofetil, over two 8­week treatment periods 
with a 4­week intervening washout68,69 showed that this 
drug was well tolerated, but there was no clinical benefit.58 
A trial in nine children with CLN1 disease that tested the 
com bination of phospho cysteamine and N­acetylcysteine, 
reported no clinical benefit (table 2).57 Thus, to date no 
efficacy is supported for any of these pharmacological 
treatments. Rather than targeting secondary downstream 
effects (eg, build up of storage material) focus should 
be directed to understanding the underlying disease 
mechanisms.
Applying a classic drug discovery approach (from disease 
mechanism to target to drug) to the NCLs is challenging 
because little is known about which intracellular pathways 
are affected or if they are good candidates for drug therapy. 
In addition, drugs need to cross the blood–brain barrier to 
reach the brain. Mole cular pathways common to neuro­
degenerative diseases (neuroinflammation, impairment of 
autophagy, defects in endocytic trafficking, mitochondrial 
alterations, or im pairment in calcium homoeostasis)72,73 
might be promis ing targets and could be entry points to 
cell­based phenotypic screening approaches. For example, 
Study title and NCT number Treatment Phase and status N Location Outcome
CLN1 Cystagon to treat infantile neuronal ceroid lipofuscinosis 
(a combination therapy with cystagon and 
N-acetylcysteine for INCL patients), NCT00028262
Mercaptamine 4, published 9 USA Little or no clinical benefit55 
CLN1 and CLN2 Study of human central nervous system stem cells 
(HuCNS-SC) cells in patients with infantile or late 
infantile neuronal ceroid lipofuscinosis, NCT00337636
Stem cells 1, published 6 USA Little or no clinical benefit56
CLN1 Safety and efficacy study of human central nervous 
system stem cells in subjects with neuronal ceroid 
lipofuscinosis, NCT01238315
Stem cells 1, withdrawn prior 
to enrolment
0 USA ..
CLN2 Safety study of a gene transfer vector for children with 
late infantile neuronal ceroid lipofuscinosis, 
NCT00151216
AAV2CUhCLN2 gene transfer 1,, published 10 USA Little or no clinical benefit57
CLN2 Safety study of a gene transfer vector (rh.10) for children 




1, ongoing 25 USA ..
CLN2 AAVrh.10 administered to children with late infantile 
neuronal ceroid lipofuscinosis with uncommon 




1/2, ongoing 8 USA ..
CLN2 A phase 1/2 open-label dose-escalation study to evaluate 
safety, tolerability, pharmacokinetics, and efficacy of 
intracerebroventricular BMN 190 in patients with late-






1/2, published 24 Germany, UK, Italy, 
USA
Clinical improvement or 
stabilization28
FDA and EMA approval
CLN2 A multicenter, multinational, extension study to evaluate 
the long-term efficacy and safety of BMN 190 in patients 





1/2, ongoing 23 Germany, UK, Italy, 
USA
..
CLN2 A safety, tolerability, and efficacy study of 






2, ongoing 15 Germany, Italy, USA ..
CLN3 Cellcept for treatment of juvenile neuronal ceroid 
lipofuscinosis, NCT01399047
Mycophenolate mofetil 2, published 19 USA Little or no clinical benefit58 
CLN6 Phase I/IIa gene transfer clinical trial for variant late 
infantile neuronal ceroid lipofuscinosis, delivering the 
CLN6 gene by self-complementary AAV9, NCT02725580
scAAV9.CB.CLN6 gene 
transfer
1/2, ongoing 12 USA ..
NCL & other 
diseases
UCB transplant of inherited metabolic diseases with 
administration of intrathecal UCB derived 
oligodendrocyte-like cells (DUOC-01), NCT02254863
Adjunct therapy for UCB-
derived oligodendrocyte-like 
cells (DUOC-01) to HSCT
1, ongoing 12 USA
NCL & other 
diseases
Human placental-derived stem cell transplantation, 
NCT01586455
Stem cells (administered in 
conjunction with umbilical 
cord blood stem cells)
1, ongoing 43 USA
CLN=neural ceroid lipofuscinosis type; NCL=neuronal ceroid lipofuscinosis; HSCT=haematopoietic-stem-cell transplantation.
Table 2: Clinical trials assessing treatment of neuronal ceroid lipofuscinoses 
a screen of bioactive compounds using cells from the 
Cln3 mouse model that had elevated levels of a marker 
protein for autophagy identified modulators of autophagy 
that included some known to target ion channels and 
especially calcium channels and proteolysis inhibitors.74,75 
Discovery of transcriptional regulation of lysosomal bio­
genesis and degradative function by the transcription 
factor EB has opened a new avenue for therapeutic inter­
vention in lysosomal storage disorders.76–79 For example, 
stimulation of transcription factor EB with trehalose 
affords benefits in Cln378 and mucopoly saccharidosis type 
III80 disease mice. The FDA­approved lipid­lowering drug 
gemfibrozil a lso a ctivates t he s ame p athway81,82 a nd h as 
moderate beneficial effects in Cln2 mice.83,84 A clinical trial 
to test efficacy of these approaches is yet to be launched in 
patients with any form of NCLs. Drug approaches for 
NCLs could com pensate for missing functional activities 
and slow or prevent cell death and these treatments will 
probably be used to supplement other treatments and 
methods such as gene therapy.
Cell-based therapy
Although the original hope of cell­based therapy lies in its 
theoretical ability to replace cells lost in advanced disease, 
the degree of replacement required for lost CNS neurons 
would need to be substantial. However, this seems unlikely 
to happen because the therapy is not capable of  replacing 
enough cells in the brain of a mouse (which is smaller 
than  a human brain and its regions are easier to reach) 
which makes it unlikely that sufficient ce ll re population 
will happen in a human brain.63 The aim of stem cell trials 
for the NCLs is to preserve remaining function by 
providing cells that secrete a missing lysosomal enzyme.64 
These cell factories will either need to be located where the 
enzyme is needed (eg, in the brain or eye) or the secreted 
enzyme will need to be transported in the blood and taken 
up by distant tissues (eg, heart), and will need to cross the 
blood–brain barrier to reach the brain. Ideally, such cells 
would be derived from an individual patient, manipulated 
to produce the required product by an introduced vector or 
by correcting the cell’s own genome, and then being 
reintroduced. A phase 1 trial established the safety of 
neuroprogenitor cell implanta tion in six patients with 
advanced CLN1 or CLN2 disease (table 2).56 There was no 
clinical benefit t o t his t rial, p erhaps b ecause d onor 
engraftment was low and migration limited.56 There is an 
ongoing phase 1 trial (NCT01586455) testing whether 
transplantation of human placental­derived stem cells 
benefits patients with a range of diseases including NCLs 
(table 2).
Conclusions and future directions
The genetic basis of the NCLs is now well understood with 
the underlying genes encoding mainly lysosomal enzymes 
or membrane proteins. Correlation of genotype with 
clinical phenotype has broadened recognition of an NCL 
disorder, and at the same time provided the gene­based 
focus and consideration of pathological targets required 
for therapeutic advances. This knowledge has prompted 
therapeutic development beyond current palliative treat­
ments, even without understanding disease mech anisms. 
Strategies for treatment of NCLs caused by defects in 
lysosomal enzymes benefit from the process of cross­
correction, leading to the first approved treatment for 
CLN2 disease that delivers recombinant protein directly 
into the brain at regular intervals. Development of a gene 
supplement approach is at the experimental stage for 
many NCLs, with the first of an anticipated new wave of 
clinical trials focusing on CLN6 disease. The results of 
clinical trials using pharmacological treatments are less 
convincing, perhaps because primary disease targets or 
pathways remain to be elucidated. Cell­based therapies 
have the potential to deliver lysosomal enzymes continually, 
and might be especially useful for treatment beyond the 
CNS, but they are in the early stages of development.
To have a long­term clinical benefit, treatment for the 
NCLs must begin early, ideally before any symptoms. This 
will require rapid and earlier diagnosis, which is aided by 
advances in DNA­based approaches, and highlights the 
importance of developing appropriate newborn screen­
ing.85,86 It will also be important to consider patients with 
milder and adult onset NCL forms who might particularly 
benefit from new treatments because there is a longer 
time window to diagnose patients before symptoms 
advance too far and are irreversible.19 International 
cooperation is contributing to the ongoing collection of 
natural history data for all NCL types into the DEM­CHILD 
database which can provide necessary control data for use 
in future clinical trials and increase understanding of the 
spectrum of each genetic type.10 A natural history database 
helps to solve the ethical dilemma of treating a proportion 
of trial patients with placebo because these patients’ 
symptoms would advance so quickly that there would be 
no hope of recovery once actual treatment starts, and 
speeds up the development of therapy options in rare 
diseases for which availability of suitable patients for a trial 
can be a limiting factor.
Treatment for NCLs must reach the most affected cells 
in the brain and eye, and further studies are needed to fully 
understand the burden of disease outside the CNS and the 
need to target the periphery. Fortunately, new vectors 
are emerging for gene supplementation therapies that 
Search strategy and selection criteria
We searched PubMed for articles only written in the English 
language and published between Jan 1, 2012, and 
Sept 30, 2018, using the search terms “ceroid”, “Batten”, 
“NCL”, “CLN”, ”PPT1”, “TPP1”, “DNAJC5”, “MFSD8”, “CTSD”, 
“GRN”, “CTSF”, “CLN1”, “CLN2”, “CLN3”, “CLN4”, “CLN5”, 
“CLN6”, “CLN7”, “CLN8”, “CLN10”, “CLN11”, “CLN12”, and 
“CLN13”. The final reference list was generated on the basis of 
relevance to the topics covered in this Review.
increase the ability to deliver treatments to cells within the 
brain or eye.87 This needs to be balanced against toxicity 
arising from producing too much recombinant protein 
within sensitive cells.88 An ideal least­invasive therapy 
would be a set of one­off or infrequent gene therapies that 
together target the whole body and are supplemented by 
probably lifelong drug­based modulation. Understanding 
of the molecular basis of the NCLs and the means to assess 
the effectiveness of any new treatment at a molecular level 
should be a future priority. This step is required for a 
breakthrough in pharmacological treatments that target 
pathways close to the underlying defect. Such advances 
will be beneficial for basic research, early diagnosis, and 
disease prevention.
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